Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms

Annals of Surgical Oncology

Volumn 22, Issue 8, 2015, Pages 2578-2584

  Choe, J H ^a   Overman, M J ^b   Fournier, K F ^b   Royal, R E ^b   Ohinata, A ^b   Rafeeq, S ^b   Beaty, K ^b   Phillips, J K ^b   Wolff, R A ^b   Mansfield, P F ^b   Eng, C ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; IRINOTECAN; PANITUMUMAB; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLINIC ACID; PLATINUM COMPLEX; VASCULOTROPIN A;

ADULT; AGED; APPENDICEAL EPITHELIAL TUMOR; APPENDIX CANCER; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGISTRY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CYTOREDUCTIVE SURGERY; DISEASE CONTROL; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; ADENOCARCINOMA, MUCINOUS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APPENDICEAL NEOPLASMS; BLOOD; CARCINOMA, SIGNET RING CELL; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; SECONDARY; SURVIVAL RATE; TUMOR VOLUME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; BEVACIZUMAB; CA-19-9 ANTIGEN; CAMPTOTHECIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SIGNET RING CELL; CETUXIMAB; CISPLATIN; CYTOREDUCTION SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM GRADING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938288955     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4335-9     Document Type: Article

References (12)

1. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240:278–85.
2. Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116:316–22.
3. Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23:652–8.
4. Stewart JHt, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34.
5. Esquivel J, Sugarbaker PH. Clinical presentation of the pseudomyxoma peritonei syndrome. Br J Surg. 2000;87:1414–8.
6. Shaheen RM, Tseng WW, Vellagas R, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol. 2001;18:221–6.
7. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 1999;5:3364–8.
8. Logan-Collins JM, Lowy AM, Robinson-Smith TM, et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol. 2008;15:738–44.
9. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
10. Eng C, Blackham AU, Overman MJ, et al. Systemic chemotherapy in the setting of unresectable appendiceal epithelial neoplasms (AEN). ASCO Meeting Abstracts. 2012;30:568.
11. Primrose JN, Falk S, Finch-Jones M, et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: the new EPOC study. ASCO Meeting Abstracts. 2013;31:3504.
12. Choe J, Blackham AU, Overman M, et al. Systemic chemotherapy in the setting of unresectable appendiceal neoplasms (AEN). Gastrointestinal Cancer Res. In press.